Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × fludarabine phosphate × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

NIH 28 OTHER 27 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Leukemia, Myeloid, Acute 7 Leukemia 5 Lymphoma 4 Leukemia, Biphenotypic, Acute 4 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, B-Cell 2 Hodgkin Disease 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Anemia, Refractory, with Excess of Blasts 2 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1

Interventions

pembrolizumab 146 Nivolumab 98 Ipilimumab 82 Dacarbazine 40 trametinib 34 dabrafenib 30 Vemurafenib 28 atezolizumab 21 binimetinib 19 Temozolomide 19 cemiplimab 16 Paclitaxel 15 cobimetinib 14 spartalizumab 13 encorafenib 12 Cisplatin 12 Carboplatin 12 Cyclophosphamide 10 talimogene laherparepvec 9 lenvatinib 9 durvalumab 9 Docetaxel 9 tremelimumab 8 relatlimab 8 Gemcitabine 8 Drug Therapy 8 Bevacizumab 8 Pemetrexed 7 Albumin-Bound Paclitaxel 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06961786 2026-03-05

TUNINTIL-2

TILT Biotherapeutics Ltd.

Phase 1 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡